In the heart, function of the sarco(endo)plasmic Ca 2ϩ -ATPase (SERCA2) is closely linked to contractility, cardiac function, and aerobic fitness. SERCA2 function can be increased by high-intensity interval training, whereas reduced SERCA2 abundance is associated with impaired cardiac function. The working hypothesis was, therefore, that exercise training before cardiomyocyte-specific disruption of the Serca2 gene would delay the onset of cardiac dysfunction in mice. Before Serca2 gene disruption by tamoxifen, untreated SERCA2 knockout mice (Serca2 flox/flox Tg-␣MHC-MerCreMer; S2KO), and SERCA2 FF control mice (Serca2 flox/flox , S2FF) were exercise trained by high-intensity interval treadmill running for 6 wk. Both genotypes responded to training, with comparable increases in maximal oxygen uptake (V O2max; 17%), left ventricle weight (15%), and maximal running speed (40%). After exercise training, cardiac-specific Serca2 gene disruption was induced in both exercise trained and sedentary S2KO mice. In trained S2KO, cardiac function decreased less rapidly than in sedentary S2KO. V O2max remained higher in trained S2KO the first 15 days after gene disruption. Six weeks after Serca2 disruption, cardiac output was higher in trained compared with sedentary S2KO mice. An exercise-training program attenuates the decline in cardiac performance induced by acute cardiac Serca2 gene disruption, indicating that mechanisms other than SERCA2 contribute to the favorable effect of exercise training. SERCA; conditional knockout; maximal oxygen uptake; tamoxifen; cardiac output THE CARDIAC SARCO(ENDO)PLASMIC calcium ATPase (SERCA2) is a major determinant of cardiac contractility and relaxation, sequestering Ca 2ϩ into the sarcoplasmic reticulum (SR) and refilling the SR calcium store (5a, 24, 27). Cardiac SERCA2 protein is therefore regarded as central for sustaining heart function and pumping capacity (24, 30) . Several studies show that high-intensity exercise training increases aerobic capacity measured as maximal oxygen uptake (V O 2max ), improves myocardial function, and enhances work performance in rodents and humans (1, 15, 17, 21, 32) . Some studies have shown that high-intensity exercise training increases SERCA2 protein abundance in the myocardium of healthy rats and mice and in failing rat hearts after myocardial infarction (17, 18, 30, 31) . In contrast, impaired cardiac contractility and lower fitness levels are associated with reduced SERCA2 activity and/or abundance in post-infarction failing myocardium (6). In a new genetically modified mouse model, heart failure is induced by acute disruption of the Serca2 gene in the myocardium by tamoxifen treatment (S2KO) (2). SERCA2 protein abundance is rapidly reduced to Ͻ5% of control values within 4 wk. S2KO mice develop severe cardiac dysfunction with reduced cardiomyocyte contractility, pulmonary congestion, dilated left atrium, and altered end-diastolic pressure within 6 -7 wk (2, 12, 13, 26). Recently, our laboratory showed that these mice tolerated high-intensity exercise training. Despite a reduction in V O 2max , training S2KO maintained maximal running speed and had a smaller decline in cardiac output than sedentary mice for up to 6 wk (12).
SERCA; conditional knockout; maximal oxygen uptake; tamoxifen; cardiac output THE CARDIAC SARCO(ENDO)PLASMIC calcium ATPase (SERCA2) is a major determinant of cardiac contractility and relaxation, sequestering Ca 2ϩ into the sarcoplasmic reticulum (SR) and refilling the SR calcium store (5a, 24, 27) . Cardiac SERCA2 protein is therefore regarded as central for sustaining heart function and pumping capacity (24, 30) . Several studies show that high-intensity exercise training increases aerobic capacity measured as maximal oxygen uptake (V O 2max ), improves myocardial function, and enhances work performance in rodents and humans (1, 15, 17, 21, 32) . Some studies have shown that high-intensity exercise training increases SERCA2 protein abundance in the myocardium of healthy rats and mice and in failing rat hearts after myocardial infarction (17, 18, 30, 31) . In contrast, impaired cardiac contractility and lower fitness levels are associated with reduced SERCA2 activity and/or abundance in post-infarction failing myocardium (6) . In a new genetically modified mouse model, heart failure is induced by acute disruption of the Serca2 gene in the myocardium by tamoxifen treatment (S2KO) (2) . SERCA2 protein abundance is rapidly reduced to Ͻ5% of control values within 4 wk. S2KO mice develop severe cardiac dysfunction with reduced cardiomyocyte contractility, pulmonary congestion, dilated left atrium, and altered end-diastolic pressure within 6 -7 wk (2, 12, 13, 26) . Recently, our laboratory showed that these mice tolerated high-intensity exercise training. Despite a reduction in V O 2max , training S2KO maintained maximal running speed and had a smaller decline in cardiac output than sedentary mice for up to 6 wk (12) .
It has recently been demonstrated that exercise training before myocardial infarction decreased mortality in mice (8) . The present study aimed to determine whether high-intensity exercise training would delay the development of cardiac dysfunction and the reduced aerobic capacity in S2KO mice. To eliminate the possible effects on exercise training and cardiac function due to tamoxifen treatment, cardiac function was frequently tested initially after tamoxifen treatment.
MATERIALS AND METHODS
Mice. The present experiments were performed in Serca2 flox/flox Tg(␣MHC-MerCreMer) (S2KO) mice, using Serca2 flox/flox (S2FF) as controls, as recently described (2, 3) . S2KO mice are unremarkable until disruption of the Serca2 gene by tamoxifen, which leads to progressive heart failure within 6 -7 wk. S2FF mice are unaffected by tamoxifen treatment and serve as controls. Mice harboring the ␣MHC-MerCreMer transgene alone (MCM) were used as controls for a transient negative effect of tamoxifen on cardiac function and gene expression (4, 22) . The Norwegian National Committee for Animal Welfare Act, conforming to the NIH guidelines (NIH publication no.85-23, revised 1996), approved all experimental protocols. Animal handling and exercise testing and training on custom-made treadmills have previously been described (12, 21) .
Study design. The present study included six groups of S2FF and S2KO mice, in total 46 male mice (age 8 wk, weight 29 Ϯ 2 g). The mice were randomized into either high-intensity interval exercise training groups or sedentary control groups. Two groups of S2FF mice (sedentary and training), were killed after the 6-wk training program to investigate the level of the cardiac SERCA2 protein response to training. These mice were not treated with tamoxifen. The four remaining groups (sedentary and training S2FF and S2KO mice) were subjected to the 6-wk training program and tamoxifen treatment, and were also included in the follow-up period that lasted 6 wk after tamoxifen treatment (Fig. 1A) . We chose to stop the daily training at the time point for tamoxifen injection to mimic an acute cardiac event.
The time course after tamoxifen injection is a combined effect of mechanisms induced by training, detraining, and decline in cardiac performance due to Serca2 disruption (19) . Furthermore, the effect of Serca2 gene disruption might also have been confounded by significant difference in the ability to train, and exercise training was therefore stopped at the time for tamoxifen treatment.
Aerobic testing and exercise training. Mice assigned to the training program were trained for 6 wk, 5 days/wk, 60 min/day, at 85-90% of V O2max. Two V O2max tests were performed in each animal to determine the V O2max baseline level before training. Weekly tests of V O 2max were performed to adjust running speed to maintain constant relative exercise intensity. V O2max tests were performed during treadmill running in a metabolic chamber, measuring the consumed O2 and produced CO2, on days 2, 4 -7, 10, and thereafter weekly until the 6-wk endpoint. Details of the training protocols have previously been described (21) . Maximal running speed was defined as the highest speed the animals managed to run for at least 1 min during the V O2max test. V O2max data were normalized to body weight by allometric scaling to minimize intra-and inter-individual differences due to variations in body mass (29) .
Serca2 gene disruption. After 6 wk of exercise training, sedentary and trained mice received two consecutive tamoxifen injections intraperitonally (ip) (days 0 and 1, 1 mg·animal Ϫ1 ·day Ϫ1 , total dose 80 mg/kg per animal) (4) . The dose of tamoxifen used in this study was chosen to minimize the cardio-depressive MCM/tamoxifen transcriptional effects without reducing the Serca2 gene disruption efficiency (4) . Animals were observed until death at endpoint, 6 wk after tamoxifen injection. To assess the early transient effects of the MCM transgene per se with regard to cardiac function (22) and gene transcription (4), we also tested V O2max in 11 male MCM mice after injection of tamoxifen or vehicle (peanut oil) in supplementary experiments.
Echocardiography. Cardiac function was assessed by transthoracic ehocardiography, using a 35-MHz probe (Vevo770, Visual Sonics, Toronto, ON, Canada). Images were recorded under light (1.25-2.25%) isoflurane anaesthesia (Forene, Abbott, Solna, Sweden) in medical oxygen. Anaesthetic level was adjusted to maintain a respiration rate of 90 Ϯ 20 breaths/min. Temperature, respiration, and heart rate were continuously monitored. Echocardiography data were recorded at baseline before exercise training, before tamoxifen treatment, and on days 9 and 42 after tamoxifen injection. Left ventricle end-diastolic, end-systolic, and stroke volumes were measured by tracing the endocardium in the parasternal long-axis view (7) . Tissue velocities were recorded in mid-ventricular posterior wall in shortaxis view. Analyses were performed offline using the enclosed software (version 3.0.0, Visual Sonics).
Tissue collection and protein analysis. To determine the effects of training alone on myocardial protein expression, 18 untreated S2FF mice (train, n ϭ 10; sedentary, n ϭ 8) were harvested after 6 wk of exercise training. Additional animals treated with tamoxifen after the training program (S2FF, n ϭ 13; S2KO, n ϭ 15) were killed by cervical dislocation in deep isoflurane anaesthesia at the 6-wk end- Fig. 1 . Study design: training period of 6 wk, followed by tamoxifen injections and a 6-wk sedentary/detraining period for all six groups of mice. Time points for in vivo maximal oxygen uptake (V O2max; lines) and echocardiographic (stippled lines) measurements (A). Time course of V O2max (B) and maximal running speed (C) development during exercise training for the untreated sedentary and training S2FF and S2KO mice that followed the whole study intervention. Western blot (D) and quantitative data (E) of SERCA2 and NCX1 protein abundance in left ventricle myocardium for S2FF mice that were killed after the training program (without tamoxifen) and in S2FF and S2KO mice 42 days after tamoxifen. Data are means Ϯ SD. SED, sedentary; TR, trained. *Significant difference between respective genotype (P Ͻ 0.05).
point. Hearts, lungs, liver, and soleus muscle were immediately weighed and snap-frozen in liquid N2. Right tibia lengths were used for gravimetric analyses. Specific protein abundance was analyzed by Western blot, as previously described (12) .
Statistics. Data are presented as means Ϯ SD. Repeated-measurements ANOVA was made for longitudinal comparisons with Bonferroni post hoc test, and repeated-measurements two-way ANOVA was used for main effect analysis. P Ͻ 0.05 was considered statistically significant.
RESULTS
Response to exercise training. After 6 wk of high-intensity exercise training, we found a 17% increase in V O 2max (Fig. 1B) . Left ventricle weight increased by 15% in trained, untreated S2FF mice compared with sedentary mice (142 Ϯ 6 and 124 Ϯ 6 mg, respectively; P Ͻ 0.05). There was no difference in V O 2max between the mice that were killed immediately after the training program to estimate the training effects on SERCA2 and NCX1 (Na ϩ , Ca 2ϩ exchanger 1) protein abundance (without tamoxifen treatment) and the trained mice that were treated with tamoxifen (data not shown). Echocardiographic parameters such as left ventricle dimensions or fractional shortening were similar before training started (data not shown). Exercise training or tamoxifen treatment did not cause significant alterations in left ventricle dimensions in S2KO or S2FF mice (Table 1) . Maximal running speed increased by 43% in both S2FF and S2KO mice compared with sedentary controls (Fig.  1C) . Left ventricular SERCA2 protein abundance remained unchanged by training (Fig. 1D) . In exercise trained S2KO mice, maximal running speed remained significantly higher for about 3 wk after tamoxifen compared with sedentary S2KO controls (Fig. 2, D and E) .
Response to Serca2 disruption. V O 2max decreased transiently in S2KO and MCM mice during the first 4 days following tamoxifen treatment (Fig. 2A) . On day 6, V O 2max returned to baseline values in MCM mice but not in S2KO mice. There was no effect of tamoxifen in S2FF mice, which do not harbor the MCM transgene.
In S2KO mice, cardiac dysfunction was confirmed 6 wk after tamoxifen by left atrial dilation, reduced myocardial tissue contractility and relaxation (Fig. 3, E-H) , and increased lung weight (data not shown for left atrium and lungs), consistent with previous studies (2, 12) . At this time point, left ventricular weight was 119 Ϯ 3 and 101 Ϯ 3 mg for training S2FF and S2KO, respectively (P Ͻ 0.05), suggesting detraining effects after training due to lack of exercise.
V O 2max remained higher (P Ͻ 0.05) in exercise trained S2KO vs. sedentary S2KO during the first 15 days after Serca2 disruption (Fig. 2, B and C) . From day 15, the decline in V O 2max was similar in trained and sedentary S2KO mice (Fig.  2B) . Cardiac output declined progressively in both trained and sedentary S2KO after Serca2 disruption (Fig. 3A) . However, in trained S2KO, the reduction in cardiac output was smaller compared with sedentary S2KO (P Ͻ 0.05; Fig. 3A ). In addition, peak systolic and diastolic tissue velocities were less attenuated in trained S2KO than in sedentary counterpart (Fig.  3, F and H) . The protein abundance of NCX1 remained unchanged after the training period and increased similarly in trained and sedentary S2KO mice 6 wk after gene disruption, consistent with previous findings (2, 12) (Fig. 1, D and E) .
DISCUSSION
The present study shows that exercise training before induction of heart failure by cardiomyocyte-specific Serca2 gene disruption attenuates the ensuing decline in aerobic capacity, running performance, and cardiac function in mice. These results support the notion that regular exercise may significantly reduce the adverse effects of event that would normally impair cardiac function.
Exercise, V O 2max , and cardiac function. Several lines of evidence suggest that physical performance and aerobic capacity are closely related to cardiac pump function, cardiomyocyte contractility, and calcium handling. Suggested mechanisms for the improved cardiac function are adaptive hypertrophy and improved cardiomyocyte contractile function (5, 18, 31), higher myocardial SERCA2 activity (17) , and improved Ca 2ϩ cycling by increased phosphorylation of CaMKII␦ (calcium/ calmodulin-dependent kinase II␦) and phospholamban (18) . Improved contractility in cardiomyocytes is also closely linked Data are means Ϯ SD (FFSED, n ϭ 7; FFTR, n ϭ 6; KOSED, n ϭ 8; KOTR, n ϭ 8). HR, heart rate; LVDd/s, diastolic and systolic left ventricular diameter; PWd/s, diastolic and systolic left ventricular posterior wall thickness; E/A, the ratio between passive (E) and active (A) filling of the left ventricle. *Two-way ANOVA repeated measurements detected the following differences: for HR days 0 -9, main effect genotype P Ͻ 0.001, main effect training P Ͻ 0.05, and training/genotype interaction P Ͻ 0.01; for LVDd days 9 -42, genotype/ training interaction P Ͻ 0.05; and for PWs days 0 -42, main effect training P Ͻ 0.01.
to alterations in intracellular pH and energy metabolism (16, 20, 23, 30, 31) .
SERCA2, V O 2max , and exercise. Several recent studies have confirmed that SERCA2 function is indeed important for calcium handling, cardiomyocyte contractility, and cardiac function. Cardiomyocyte-specific disruption of the Serca2 gene leads to a progressive decline in diastolic function, depressed systolic and diastolic myocardial tissue velocities, and decreased cardiac output, and ultimately severs cardiac dysfunction (2) . A recent study from our laboratory showed that the time course of decreased V O 2max paralleled the time course of reduced cardiomyocyte contractility described by Andersson and colleagues (2, 12) . S2KO mice have a near-normal systolic function up to 4 wk after Serca2 disruption, with increased NCX1 and L-type Ca 2ϩ -channel function (2, 12, 26) . These findings suggest that increased sarcolemmal Ca 2ϩ handling is able to sustain systolic Ca 2ϩ decay and relaxation rates in S2KO mice when SERCA2 protein abundance declines (2, 26).
SERCA2, V O 2max
, and exercise. An increase in V O 2max induced by training is correlated to increased cardiac function. Previous studies from our laboratory suggested that this improved contractile function after an exercise-training program may be associated with enhanced SERCA2 protein abundance in the cardiomyocytes (17, 18, 31) . In addition, improved cardiomyocyte contractility has been demonstrated without any increase in SERCA2 abundance (9) . Increased SERCA2 activity after exercise training has been related to the phosphorylation level of phospholamban, and the activation state of CaMKII␦. Moreover, increased cardiomyocyte contractility has been related to increased myofilament Ca 2ϩ sensitivity (11, 18, 31) . In contrast, a reduction in SERCA2 activity is expected to reduce cardiac function and hence V O 2max (5a, 24, 27, 30) . A previous study by the present authors suggested that a functional SERCA2 is not required for training-induced improvements in V O 2max but is essential to maintain and/or increase V O 2max from baseline levels (12). S2KO (A, B, D) mice. Time course of V O2max (A, B, C) and maximal running speed (D, E) after tamoxifen treatment. A: development in sedentary S2FF, S2KO, and MCM mice for days 0 -6. The decline in V O2max after tamoxifen injections was most prominent on day 4 for MCM mice, before baseline levels were reestablished. For S2KO mice, V O2max never returned to baseline levels. V O2max day 7-45 in training (TR) and sedentary (SED) S2KO mice (B), and S2FF mice (C). Maximal running speed day 7-45 in training and sedentary S2KO mice (D), and S2FF mice (E). Two-way ANOVA detected the following significant effects on V O2max. From day 0 -7, main effect of genotype was P Ͻ 0.01, and main effect training group was P Ͻ 0.01. For difference from day 7-45 and day 0 -45, P Ͻ 0.01 was valid for main effect of genotype, main effect training group, and genotype/training group interaction. For maximal running speed, two-way ANOVA detected P Ͻ 0.01, for changes between days 7 and 45 and days 0 and 45 on main effect genotype. For main effect training, P Ͻ 0.01 was valid for changes between days 0 and 7, days 7 and 45, and days 0 and 45. Data are means Ϯ SD. *P Ͻ 0.05 for repeated-measurement ANOVA in respective group.
Exercise and Serca2 disruption. Similar to previous data in exercise-trained mice, the 6-wk training program in untreated S2FF and S2KO mice increased V O 2max and induced left ventricular hypertrophy (17, 21, 28) . After gene disruption, V O 2max remained higher for the first 10 -15 days, whereupon the decrease in V O 2max was similar in trained and sedentary S2KO mice. In trained S2FF mice, V O 2max declined from day 10, probably a detraining effect secondary to lack of exercise (19) . The present study shows that a longer period of exercise training may sustain the cardio-protective benefits for a longer time than shorter exercise programs (14, 25) . However, the present study could not exclude that part of the preserved aerobic capacity may derive from improved work economy and skeletal muscle adaptations, such as increased oxygen extraction and improved energy production (12) . Optimally, the arterio-venous oxygen difference would have been measured, but this was beyond the scope of the present study.
We have recently shown that tamoxifen-induced cardiomyocyte-specific disruption of the Serca2 gene results in a smaller reduction in cardiac output and better maintained running capacity in trained vs. sedentary S2KO mice (12) . These changes were associated with a slower decline in V O 2max , indicating that a normal level of SERCA2 activity is not decisive for maintaining and/or increasing V O 2max and cardiac performance (12) . Since SERCA2 and NCX1 protein abundance was altered by the training period in the S2KO Fig. 3 . Echocardiographic assessments in S2FF and S2KO mice at days 0, 9, and 42 after tamoxifen treatment. Cardiac output (A, B), stroke volume (C, D), left ventricle posterior peak systolic (E, F), and peak diastolic (G, H) tissue velocity in S2FF (left) and S2KO (right) mice. Two-way ANOVA detected the following significant effects between days 0 and 42 (*). For cardiac output, main effect of genotype was P Ͻ 0.05, and for main effect of training, it was P Ͻ 0.05. For stroke volume, main effect of genotype was P Ͻ 0.05, and for main effect genotype/ training interaction there was a trend (P ϭ 0.07). For peak systolic velocity, main effect of genotype was P Ͻ 0.01, and for peak diastolic velocity, main effect of genotype/training interaction was P Ͻ 0.05. TR, training; SED, sedentary. Data are means Ϯ SD. mice, the smaller reduction in cardiac output in trained S2KO compared with sedentary S2KO is not likely to be a result of increased SERCA2 and/or NCX1 levels. However, we cannot exclude that training attenuated the SERCA2 protein decline in the tamoxifen-treated animals or temporarily contributed to the compensatory increase in NCX1 protein. Moreover, the increase in NCX1 protein may be a compensatory mechanism for Serca2 gene disruption that is independent of exercise training (2, 12, 26) . These findings suggest that other mechanisms than enhanced SERCA2 function may contribute to the beneficial effects of exercise training.
High-intensity interval training is suggested to increase the myofilament Ca 2ϩ sensitivity, thereby improving the maximal and submaximal tension of the sarcomere, and thereby restoring calcium-handling proteins (10, 11, 31) .
MCM transgene and tamoxifen effects on cardiac function. Recent reports have shown that tamoxifen induces a transient cardio-depressive effect in mice harboring the MCM transgene (4, 22) . In MCM mice, we found that the transient decrease in V O 2max returned to baseline after 5 days, i.e., 3 days after the last tamoxifen dose. Thus the difference in V O 2max between MCM and S2KO after 5 days would reflect the effect of Serca2 gene disruption rather than negative MCM/tamoxifen effects. In contrast, tamoxifen had negligible effects on V O 2max in S2FF mice, which do not harbor the MCM-transgene.
Study limitations
In the present study, tissue was not available between days 0 and 42 to follow the abundance of SERCA2 and NCX1. However, previous studies have shown the time course of declining SERCA2 and increased NCX1 abundance after Serca2 gene disruption after tamoxifen treatment (2, 4, 12, 26) . Possible tamoxifen effects are not considered in a long-time perspective after exercise cessation and should be addressed in a further study.
In conclusion, mice with enhanced cardiac function due to exercise training are better fit to withstand the cardiomyopathy induced by Serca2 gene disruption. Exercise training attenuates the decline in cardiac function in S2KO mice supported by a prolonged improvement in V O 2max and a less attenuated cardiac output.
